237 related articles for article (PubMed ID: 36942272)
1. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
2. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
3. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
4. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
[TBL] [Abstract][Full Text] [Related]
5. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
6. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
7. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models.
Seo JE; Yu JZ; Xu H; Li X; Atrakchi AH; McGovern TJ; Bruno KLD; Mei N; Heflich RH; Guo X
Arch Toxicol; 2023 Oct; 97(10):2785-2798. PubMed ID: 37486449
[TBL] [Abstract][Full Text] [Related]
9. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
[TBL] [Abstract][Full Text] [Related]
10. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
Kalauz A; Tiringer KV; Horváth V; Kapui I
J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
[TBL] [Abstract][Full Text] [Related]
12. A Cautionary Tale: Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin.
Yang J; Marzan TA; Ye W; Sommers CD; Rodriguez JD; Keire DA
AAPS J; 2020 Jul; 22(4):89. PubMed ID: 32613429
[TBL] [Abstract][Full Text] [Related]
13. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
Gopireddy RR; Maruthapillai A; Mahapatra S
J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
[TBL] [Abstract][Full Text] [Related]
14. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
Sharma N; Patel R; Bothara T; Jain S; Shah RP
J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
16. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
17. Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications.
Li K; Ricker K; Tsai FC; Hsieh CJ; Osborne G; Sun M; Marder ME; Elmore S; Schmitz R; Sandy MS
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574388
[TBL] [Abstract][Full Text] [Related]
18. Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity.
Glowienke S; Onken U; Elhajouji A; Muthusamy S; Sangana R; Martus HJ; Bedman T; Hartmann A
Regul Toxicol Pharmacol; 2022 Oct; 134():105245. PubMed ID: 35988810
[TBL] [Abstract][Full Text] [Related]
19. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
[TBL] [Abstract][Full Text] [Related]
20. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]